EVX-04 — IND submission
Late 2026
In parallel with preclinical studies, we are preparing the regulatory filing for clinical testing of EVX-04, which is expected to be submitted before the end of the year.Source filing
EVAX biotech catalysts & pipeline
EVAXION A · Data as of 2026-10-25
Upcoming catalysts
EVX-B4 — Conference presentation
H2 2026
In our infectious disease pipeline, the most significant expected event is the design and preclinical validation of antigens for our Group A Streptococcus vaccine, EVX-B4, with new data anticipated to be presented at a conference in the second half of the year.Source filing
EVX-01 — Conference presentation
Oct 23–Oct 27
The data will be presented in a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026 held in Madrid, Spain, tomorrow.Source filing
AI-Immunology™ — Conference presentation
Nov 18
Initial experimental data will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 2026Source filing